PDL Biopharma in $92.5 million settlement with MedImmune to resolve disputes on Synagis claims
This article was originally published in Scrip
Executive Summary
PDL Biopharma says it has made a $92.5 million settlement with MedImmune, a subsidiary of AstraZeneca, to resolve all legal disputes between the two parties, including those related to MedImmune's respiratory syncytial virus drug Synagis (palivizumab) and PDL's patents. PDL added that MedImmune will not pay any further royalties on sales of the product.